FI990875A0 - CD4-spesifinen yhdistelmävasta-aine - Google Patents

CD4-spesifinen yhdistelmävasta-aine

Info

Publication number
FI990875A0
FI990875A0 FI990875A FI990875A FI990875A0 FI 990875 A0 FI990875 A0 FI 990875A0 FI 990875 A FI990875 A FI 990875A FI 990875 A FI990875 A FI 990875A FI 990875 A0 FI990875 A0 FI 990875A0
Authority
FI
Finland
Prior art keywords
antibody
pref
derived
chain
cdr
Prior art date
Application number
FI990875A
Other languages
English (en)
Swedish (sv)
Other versions
FI990875A (fi
FI109768B (fi
Inventor
Linda Kay Jolliffe
Robert Allan Zivin
Virginia Lee Pulito
John Robert Adair
Diljeet Singh Athwal
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10668300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI990875(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of FI990875A publication Critical patent/FI990875A/fi
Publication of FI990875A0 publication Critical patent/FI990875A0/fi
Application granted granted Critical
Publication of FI109768B publication Critical patent/FI109768B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI990875A 1989-12-21 1999-04-19 CD4-spesifinen yhdistelmävasta-aine FI109768B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB8928874 1989-12-21
GB898928874A GB8928874D0 (en) 1989-12-21 1989-12-21 Humanised antibodies
GB9002015 1990-12-21
PCT/GB1990/002015 WO1991009966A1 (en) 1989-12-21 1990-12-21 Cd4 specific recombinant antibody
FI913932A FI108917B (fi) 1989-12-21 1991-08-20 Menetelmä terapeuttisesti käyttökelpoisten CD4-spesifisen yhdistelmävasta-aineen valmistamiseksi
FI913932 1991-08-20

Publications (3)

Publication Number Publication Date
FI990875A FI990875A (fi) 1999-04-19
FI990875A0 true FI990875A0 (fi) 1999-04-19
FI109768B FI109768B (fi) 2002-10-15

Family

ID=10668300

Family Applications (4)

Application Number Title Priority Date Filing Date
FI913932A FI108917B (fi) 1989-12-21 1991-08-20 Menetelmä terapeuttisesti käyttökelpoisten CD4-spesifisen yhdistelmävasta-aineen valmistamiseksi
FI913926A FI108777B (fi) 1989-12-21 1991-08-20 Menetelmä CDR-siirteellä muokatun vasta-ainemolekyylin tuottamiseksi
FI913927A FI108776B (fi) 1989-12-21 1991-08-20 Menetelmä anti-CD3-CDR-siirteellä muokatun vasta-ainemolekyylin tuottamiseksi
FI990875A FI109768B (fi) 1989-12-21 1999-04-19 CD4-spesifinen yhdistelmävasta-aine

Family Applications Before (3)

Application Number Title Priority Date Filing Date
FI913932A FI108917B (fi) 1989-12-21 1991-08-20 Menetelmä terapeuttisesti käyttökelpoisten CD4-spesifisen yhdistelmävasta-aineen valmistamiseksi
FI913926A FI108777B (fi) 1989-12-21 1991-08-20 Menetelmä CDR-siirteellä muokatun vasta-ainemolekyylin tuottamiseksi
FI913927A FI108776B (fi) 1989-12-21 1991-08-20 Menetelmä anti-CD3-CDR-siirteellä muokatun vasta-ainemolekyylin tuottamiseksi

Country Status (21)

Country Link
US (10) US5929212A (fi)
EP (5) EP0460171B1 (fi)
JP (4) JPH04505398A (fi)
KR (3) KR100197956B1 (fi)
AT (4) ATE159299T1 (fi)
AU (4) AU649645B2 (fi)
BG (1) BG60462B1 (fi)
BR (1) BR9007197A (fi)
CA (3) CA2046904C (fi)
DE (4) DE69033857T2 (fi)
DK (4) DK0460171T3 (fi)
ES (4) ES2112270T3 (fi)
FI (4) FI108917B (fi)
GB (4) GB8928874D0 (fi)
GR (2) GR3017734T3 (fi)
HU (4) HU215383B (fi)
NO (5) NO316076B1 (fi)
RO (3) RO114298B1 (fi)
RU (1) RU2112037C1 (fi)
WO (3) WO1991009966A1 (fi)
ZA (1) ZA9110129B (fi)

Families Citing this family (1309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
WO1992009305A1 (en) * 1990-11-27 1992-06-11 Biogen, Inc. Anti cd-4 antibodies blocking hiv-induced syncytia
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9104498D0 (en) * 1991-03-04 1991-04-17 Ks Biomedix Ltd Antibody
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
ES2289997T3 (es) * 1991-03-18 2008-02-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
WO1993012220A1 (en) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
WO1995014041A1 (fr) 1993-11-19 1995-05-26 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre des cellules medulloblastomateuses humaines
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
DE69530763T2 (de) 1994-03-29 2004-02-26 Celltech Therapeutics Ltd., Slough Antikörper gegen e-selektin
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
CA2182946A1 (en) 1994-12-23 1996-07-04 Raymond John Owens Human phosphodiesterase type ivc, and its production and use
WO1996020219A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
PT840618E (pt) * 1995-05-18 2003-08-29 Ortho Mcneil Pharm Inc Inducao de tolerancia imunologica atraves de anticorpos anti-cd4 nao-depletores
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP0833911B1 (en) * 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
ATE483733T1 (de) * 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
RO123028B1 (ro) * 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Anticorpi umani, care leagă tnf alpha uman
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998012329A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP1862548A1 (en) 1997-01-28 2007-12-05 Human Genome Sciences, Inc. Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L)
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
CA2644454A1 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3957765B2 (ja) * 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE541586T1 (de) * 1997-04-07 2012-02-15 Genentech Inc Behälter mit anti-vegf antikörpern
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
WO1999018212A1 (fr) * 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Anticorps humain naturel
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
PL343322A1 (en) * 1998-04-03 2001-08-13 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
DE69909459T2 (de) 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
AU771539C (en) 1998-10-06 2005-01-13 Dyadic International (Usa), Inc. Transformation system in the field of filamentous fungal hosts
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2350454T3 (es) 1998-11-27 2011-01-24 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la sustancia ósea.
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003509078A (ja) * 1999-09-22 2003-03-11 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 細胞に基づくアッセイ
US7253263B1 (en) * 1999-09-30 2007-08-07 Kyowa Hakko Kogyo Co., Ltd. Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
DE60130538T2 (de) * 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP1783227A1 (en) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
DE60106394T3 (de) 2000-02-24 2013-07-25 Washington University St. Louis Humanisierte antikörper, die amyloid beta peptid sequestrieren
EP1259547B1 (en) * 2000-03-01 2012-07-11 Medimmune, Inc. High potency recombinant antibodies and method for producing them
CA2401993A1 (en) * 2000-03-02 2001-09-07 Abgenix, Inc. Human monoclonal antibodies against oxidized ldl receptor and pharmaceutical uses thereof
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
WO2001079480A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001081401A1 (fr) 2000-04-21 2001-11-01 Fuso Pharmaceutical Industries, Ltd. Nouvelles collectines
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP1294769B1 (en) 2000-06-16 2011-01-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
TR200602095T2 (tr) 2000-10-13 2007-02-21 Biogen Idec Ma Inc. Hümanize Anti-LT-Beta-R antikorları
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP2027874B1 (en) 2000-11-28 2013-10-16 Medimmune, Inc. Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
UY27087A1 (es) 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20020147312A1 (en) * 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
DK1411962T3 (da) * 2001-03-15 2011-04-04 Neogenix Oncology Inc Terapi for pancreacancer med monoklonalt stof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
EP1385864B1 (en) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
NZ529359A (en) 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1420032B2 (en) † 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
DE60238497D1 (de) * 2001-09-14 2011-01-13 Fraunhofer Ges Forschung Immunglobulin mit einem bestimmten rahmengerüst und verfahren zu dessen herstellung und verwendung
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
JP4443923B2 (ja) * 2001-10-15 2010-03-31 イミューノメディクス、インコーポレイテッド 親和性向上剤
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
WO2003063768A2 (en) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
ATE395413T1 (de) * 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
CA2469196A1 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Discovery of therapeutic products
AU2002357779A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2003092597A2 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
PL224001B1 (pl) * 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2003099226A2 (en) 2002-05-28 2003-12-04 Celltech R & D Limited Antibody peg positional isomers, compositions comprising same, and use thereof
CA2488682C (en) 2002-06-10 2014-04-01 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2487321A1 (en) 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003248782A1 (en) 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
US20040136990A1 (en) * 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of pain using TNFalpha inhibitors
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
WO2004019886A2 (en) 2002-08-29 2004-03-11 Cytocure Llc Methods for up-regulating antigen expression in tumors
AU2003282752A1 (en) 2002-10-08 2004-05-04 Immunomedics, Inc. Antibody therapy
DK2891666T3 (en) 2002-10-16 2017-10-02 Purdue Pharma Lp Antibodies that bind cell-associated CA 125 / O722P and methods for its use
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
AU2002368305A1 (en) * 2002-10-31 2004-05-25 Universita'degli Studi Di Roma "La Sapienza" Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
JP4757493B2 (ja) * 2002-11-13 2011-08-24 レイベン バイオテクノロジーズ，インコーポレイティド 抗原ｐｉｐａおよびそれに結合する抗体
ATE481422T1 (de) 2002-11-21 2010-10-15 Celltech R & D Inc Modulieren von immunantworten
KR20050089151A (ko) 2002-11-26 2005-09-07 프로테인 디자인 랩스 인코포레이티드 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및인간화 항체
JP4898120B2 (ja) 2002-12-20 2012-03-14 アボット バイオセラピューティクス コーポレイション Ｇｐｒ６４に対する抗体とその利用法
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2390350C2 (ru) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Активная иммунизация для создания антител к растворимому а-бета
ES2344645T3 (es) * 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2515779A1 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive method and compositions related to proteasomal interference
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
JP4628357B2 (ja) 2003-04-23 2011-02-09 メダレックス インコーポレイテッド 炎症性腸疾患治療用の組成物及び治療方法
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
MEP31408A (en) * 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
KR20120113811A (ko) * 2003-07-21 2012-10-15 이뮤노젠 아이엔씨 씨에이6 항원 특이적 세포독성 접합체 및 이를 사용하는 방법
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20050221383A1 (en) 2003-08-08 2005-10-06 Choong-Chin Liew Osteoarthritis biomarkers and uses thereof
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
PL1673398T3 (pl) * 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
EP1678314B1 (en) 2003-10-22 2012-09-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP1687338B1 (en) 2003-11-07 2010-10-20 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
WO2005054868A1 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
JP5422101B2 (ja) 2004-01-07 2014-02-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
JPWO2005068504A1 (ja) 2004-01-19 2008-01-10 株式会社医学生物学研究所 炎症性サイトカイン抑制剤
AU2005212369B2 (en) 2004-02-10 2011-06-23 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
MX2007000023A (es) 2004-06-21 2007-03-07 Medarex Inc Anticuerpos del receptor uno de interferon alfa, y sus usos.
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
EP1773391A4 (en) * 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
EP1781321B1 (en) * 2004-08-02 2014-01-08 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a vegf-b antagonist
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
AU2005277508B2 (en) 2004-08-16 2011-04-14 Quark Pharmaceuticals, Inc Therapeutic uses of inhibitors of RTP801
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP4881874B2 (ja) 2004-12-06 2012-02-22 協和発酵キリン株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用
ES2434732T3 (es) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
EP2520669A3 (en) 2005-02-07 2013-02-27 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
CA2597924C (en) 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
JP2008531730A (ja) 2005-03-04 2008-08-14 キュアーディーエム、インク． Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
EP1863531A1 (en) 2005-03-19 2007-12-12 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
NZ561883A (en) 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
EP1868650B1 (en) 2005-04-15 2018-10-03 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
WO2006121159A1 (ja) * 2005-05-12 2006-11-16 Kyowa Hakko Kogyo Co., Ltd. Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
BR122013001996B1 (pt) 2005-05-18 2022-02-01 Ablynx N.V. Nanocorpos melhorados contra fator alfa de necrose tumoral
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
WO2006122822A2 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
EA013821B1 (ru) 2005-05-25 2010-08-30 Кьюрдм, Инк. Проостровковые пептиды человека, их производные и аналоги и способы их применения
CN101227924A (zh) 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
PT2390267E (pt) * 2005-06-07 2013-07-16 Esbatech A Novartis Co Llc Anticorpos estáveis e solúveis que inibem tnf(alfa)
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CN103145840A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1912675B1 (en) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-cell reduction using cd37-specific and cd20-specific binding molecules
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
PT1919503E (pt) 2005-08-10 2015-01-05 Macrogenics Inc Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2500359A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101026016B1 (ko) 2005-09-29 2011-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｔ 세포 접착 분자 및 이에 대한 항체
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
TW200730825A (en) 2005-10-21 2007-08-16 Genenews Inc Method and apparatus for correlating levels of biomarker products with disease
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
JP2009514888A (ja) 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
CN101500592A (zh) 2005-11-07 2009-08-05 斯克利普斯研究院 控制组织因子信号转导特异性的组合物和方法
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
ES2524984T3 (es) 2005-11-30 2014-12-16 Abbvie Inc. Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
PE20070998A1 (es) 2005-12-09 2007-10-09 Ucb Pharma Sa Moleculas de anticuerpo que tienen especificidad para la il-6-humana
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101370827B (zh) 2005-12-21 2015-10-14 麦克罗梅特股份公司 具有cea抗性的药物组合物
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
EP1991274A4 (en) 2006-01-20 2009-06-10 Women S And Children S Health METHOD FOR THE TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF BONE DISEASES
DK1981902T3 (en) 2006-01-27 2015-10-05 Biogen Ma Inc Nogo Receptor Antagonists
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2007226696C1 (en) 2006-03-10 2016-02-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
ES2424468T3 (es) 2006-03-27 2013-10-02 Medimmune Limited Miembro de unión para el receptor GM-CSF
BRPI0709726A2 (pt) * 2006-04-05 2011-07-26 Abbott Biotechnology Ltd. purificaÇço de anticorpo
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
AU2007258694B2 (en) * 2006-06-06 2011-12-22 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP2815764A1 (en) 2006-06-14 2014-12-24 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
SI2029173T1 (sl) * 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
AU2007276294B2 (en) 2006-06-30 2012-11-29 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
KR101440795B1 (ko) 2006-06-30 2014-09-22 애브비 바이오테크놀로지 리미티드 자동 주사 장치
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
ES2371495T3 (es) 2006-07-24 2012-01-03 Biorexis Pharmaceutical Corporation Proteínas de fusión de exendina.
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
KR101437188B1 (ko) 2006-08-04 2014-10-02 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AR062435A1 (es) 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
EP2292663B1 (en) 2006-08-28 2013-10-02 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
CN101522713A (zh) 2006-09-01 2009-09-02 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
TW201522372A (zh) 2006-09-08 2015-06-16 艾伯維巴哈馬有限公司 介白素-１３結合蛋白質
JP2010506842A (ja) 2006-10-16 2010-03-04 メディミューン，エルエルシー 半減期が短縮された分子、その組成物および使用
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR101154276B1 (ko) 2006-11-17 2012-07-10 사이단호진한다이비세이부쯔뵤우겐큐우카이 신경 신장 촉진제 및 신장 억제제
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
WO2008152446A2 (en) 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008086006A2 (en) 2007-01-09 2008-07-17 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008092905A2 (en) 2007-02-01 2008-08-07 Boehringer Ingelheim International Gmbh Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2125894B1 (en) 2007-03-22 2018-12-19 Biogen MA Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2164868E (pt) 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
NZ599278A (en) 2007-05-14 2013-12-20 Medimmune Llc Methods of reducing eosinophil levels
KR101523788B1 (ko) 2007-05-17 2015-06-26 제넨테크, 인크. 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
TWI561530B (en) 2007-05-21 2016-12-11 Alderbio Holdings Llc Antibodies to il-6 and use thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN107226864A (zh) 2007-06-21 2017-10-03 宏观基因有限公司 共价双抗体及其用途
GB0712503D0 (en) * 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
US8551751B2 (en) 2007-09-07 2013-10-08 Dyadic International, Inc. BX11 enzymes having xylosidase activity
BRPI0815983A2 (pt) 2007-08-29 2018-05-22 Sanofi Aventis anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
AU2008292913B2 (en) 2007-08-30 2014-06-05 Curedm Group Holdings, Llc Compositions and methods of using proislet peptides and analogs thereof
AU2008292897B2 (en) * 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
US20090136427A1 (en) 2007-09-18 2009-05-28 La Jolla Institute For Allergy And Immunology LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
RU2482876C2 (ru) 2007-10-05 2013-05-27 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5767475B2 (ja) 2007-11-05 2015-08-19 メディミューン，エルエルシー 強皮症の治療方法
EP2902494A1 (en) 2007-11-09 2015-08-05 The Salk Institute for Biological Studies Use of tam receptor inhibitors as antimicrobials
EP2586797A3 (en) 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
JP5744522B2 (ja) 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１に特異的なヒト化抗体分子
DK2222706T4 (en) 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
EP2237792B1 (en) 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
PT2238168E (pt) 2007-12-26 2014-07-18 Biotest Ag Agentes visando cd138 e suas utilizações
WO2009080830A1 (en) 2007-12-26 2009-07-02 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
WO2009080831A1 (en) 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
CN101918555B (zh) * 2008-01-11 2013-11-06 株式会社遗传科技 人源化抗整联蛋白α9抗体及其应用
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
CA2711736A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
DK2250279T3 (en) 2008-02-08 2016-08-01 Medimmune Llc ANTI-IFNAR1 antibodies with reduced Fc ligand affinity-
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2260057B1 (en) 2008-03-13 2016-11-23 Biotest AG Anti-CD4 antibody dosage regimen for treating autoimmune disease
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
PL2262838T3 (pl) 2008-03-13 2016-10-31 Środek do leczenia choroby
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
WO2009119794A1 (ja) 2008-03-27 2009-10-01 タカラバイオ株式会社 感染症予防、治療剤
DK2281005T3 (en) 2008-04-03 2014-02-24 Vib Vzw Single domain antibodies able to modulate bace1 activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2009131256A1 (en) 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EP3059248A1 (en) 2008-05-09 2016-08-24 Abbvie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2297186B1 (en) 2008-05-29 2018-08-29 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Expression and assembly of human group c rotavirus-like particles and uses thereof
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2010004438A2 (en) 2008-06-16 2010-01-14 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
DK2307458T3 (en) 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
MX347972B (es) 2008-06-25 2017-05-22 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el vegf.
CN102076716A (zh) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
SG192496A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 binding proteins and uses thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US8802706B2 (en) 2008-08-07 2014-08-12 Nagasaki University Method for treating fibromyalgia
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
BRPI0919841A2 (pt) 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP2355847A1 (en) 2008-10-07 2011-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
EP2786762B1 (en) 2008-12-19 2019-01-30 MacroGenics, Inc. Covalent diabodies and uses thereof
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
CA2749966A1 (en) 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
HUE042114T2 (hu) 2009-02-17 2019-06-28 Ucb Biopharma Sprl Humán OX40-re specifikus ellenanyag-molekulák
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
EP2406285B1 (en) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
KR20110129935A (ko) * 2009-03-16 2011-12-02 세파론 오스트레일리아 피티와이 엘티디 항종양 활성을 가진 인간화된 항체
EP2408818A1 (en) 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
JPWO2010110346A1 (ja) 2009-03-24 2012-10-04 独立行政法人理化学研究所 白血病幹細胞マーカー
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
WO2010121140A1 (en) 2009-04-16 2010-10-21 Facet Biotech Corporation ANTI-TNF-α ANTIBODIES AND THEIR USES
EP2949673A1 (en) 2009-04-27 2015-12-02 Kyowa Hakko Kirin Co., Ltd. Anti-il-3ra antibody for use in treatment of blood tumor
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
ES2643034T3 (es) 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
EP2440934B1 (en) 2009-06-08 2014-07-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
ES2534355T3 (es) 2009-06-17 2015-04-21 Abbvie Biotherapeutics Inc. Anticuerpos anti-VEGF y sus usos
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
EA022788B1 (ru) 2009-07-03 2016-03-31 Бионор Иммуно Ас Новые терапевтические и диагностические средства
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
EP2464664B1 (en) 2009-08-13 2015-09-23 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
AU2010286427A1 (en) 2009-08-31 2012-03-08 Abbott Biotherapeutics Corp. Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
UY32870A (es) 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
RU2012119756A (ru) 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
IN2012DN03348A (fi) 2009-10-16 2015-10-23 Biorealites
EP2493926B1 (en) 2009-10-27 2020-03-11 UCB Biopharma SRL Function modifying nav 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
EP2493929B1 (en) 2009-10-28 2017-08-16 AbbVie Biotherapeutics Inc. Anti-egfr antibodies and their uses
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
BR112012011463A2 (pt) 2009-10-30 2017-05-02 Abbott Biotherapeutics Corp uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496257A4 (en) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd TREATMENT OF CANCER CHARACTERIZED BY THE MUTATION OF KRAS OR BRAF GENES
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CA2782459A1 (en) 2009-12-04 2011-06-09 Katholieke Universiteit Leuven, K.U.Leuven R&D Arf6 as a new target for treating alzheimer's disease
JP5951498B2 (ja) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
CN102892782B (zh) 2009-12-23 2015-01-14 4-抗体股份公司 针对人类巨细胞病毒的结合成员
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
SG183872A1 (en) 2010-03-02 2012-11-29 Abbvie Inc Therapeutic dll4 binding proteins
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AU2011231978B2 (en) 2010-03-24 2014-12-18 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP2558503B1 (en) 2010-04-14 2015-12-09 National Research Council of Canada Compositions and methods for brain delivery of analgesic peptides
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
JP6085554B2 (ja) 2010-04-16 2017-02-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗ｖｌａ−４抗体
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
PL2571532T3 (pl) 2010-05-14 2017-10-31 Abbvie Inc Białka wiążące IL-1
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
CN103347894B (zh) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 抗gd2抗体
JP2013530981A (ja) 2010-06-25 2013-08-01 アストン ユニバーシティ 脂質動員特性を有する糖タンパク質およびその治療的使用
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
TWI627964B (zh) 2010-07-09 2018-07-01 傑森疫苗防護公司 抗-人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9040671B2 (en) 2010-07-23 2015-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for cancer management targeting Co-029
AU2011284908B2 (en) 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
HUE058226T2 (hu) 2010-08-19 2022-07-28 Zoetis Belgium S A NGF elleni antitestek és alkalmazásuk
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
PL2621955T3 (pl) 2010-10-01 2018-07-31 National Research Council Of Canada Przeciwciała anty-CEACAM6 i ich zastosowania
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2632949B1 (en) 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
LT2634194T (lt) 2010-10-29 2018-10-25 Perseus Proteomics Inc. Anti-cdh3 antikūnas su dideliu gebėjimu internalizuotis
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
DK2643018T3 (da) 2010-11-23 2021-01-18 Vitaeris Inc Anti-il-6-antistoffer til behandling af oral mucositis
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
BR112013015508B1 (pt) 2010-12-20 2022-04-05 Medimmune Limited Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
EP2655417A2 (en) 2010-12-21 2013-10-30 AbbVie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
ES2632583T3 (es) 2011-01-14 2017-09-14 Ucb Biopharma Sprl Anticuerpo que se une a IL-17A e IL-17F
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US20140072557A1 (en) 2011-02-28 2014-03-13 National Cerebral And Cardiovascular Center Medicinal agent for suppressing malignant tumor metastasis
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
EA035351B1 (ru) 2011-03-31 2020-06-01 Инсэрм (Инститют Насиональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Антитела, направленные против icos, и их применения
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PT2704742T (pt) 2011-05-02 2017-11-15 Millennium Pharm Inc Formulação de um anticorpo anti-a47
KR102101806B1 (ko) 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CN108329391A (zh) 2011-05-27 2018-07-27 埃博灵克斯股份有限公司 使用rankl结合肽抑制骨质吸收
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
ES2785349T3 (es) 2011-06-10 2020-10-06 Canada Minister Nat Defence Anticuerpos anti-ricina y sus usos
JP6120833B2 (ja) 2011-06-22 2017-04-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
AU2012273954A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
JP2014520847A (ja) 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CA2847245A1 (en) 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
ES2729278T3 (es) 2011-09-16 2019-10-31 Ucb Biopharma Sprl Anticuerpos neutralizantes de las exotoxinas principales tcda y tcdb de Clostridium difficile
JP6156144B2 (ja) 2011-09-21 2017-07-05 富士レビオ株式会社 親和性複合体に対する抗体
US20150044208A1 (en) 2011-09-23 2015-02-12 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
CA2851322C (en) 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2776838A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
DK2776466T3 (da) 2011-11-11 2017-11-20 Ucb Biopharma Sprl Albuminbindende antistoffer og bindingsfragmenter deraf
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2599496A1 (en) 2011-11-30 2013-06-05 Kenta Biotech AG Novel targets of Acinetobacter baumannii
EP3712173B1 (en) 2011-12-05 2023-07-12 X-Body, Inc. Pdgf receptor beta binding polypeptides
SG11201402887SA (en) 2011-12-08 2014-07-30 Biotest Ag Uses of immunoconjugates targeting cd138
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US8865870B2 (en) 2012-01-20 2014-10-21 Genzyme Corporation Anti-CXCR3 antibodies and methods of use thereof
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
WO2013112922A1 (en) 2012-01-27 2013-08-01 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CA2864092C (en) 2012-02-10 2021-06-29 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
HUE036955T2 (hu) 2012-02-15 2018-08-28 Novo Nordisk As Antitestek, amelyek a trigger receptort kötik és blokkolják, amely Myeloid-sejteken-1 (TREM-1) van expresszálva
CN104203977A (zh) 2012-02-15 2014-12-10 诺和诺德A/S（股份有限公司） 结合肽聚糖识别蛋白1的抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6779012B2 (ja) 2012-03-28 2020-11-04 サノフイＳａｎｏｆｉ ブラジキニンｂ１受容体リガンドに対する抗体
EP2831112A1 (en) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
EP2847223B1 (en) 2012-05-07 2019-03-27 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2013172951A1 (en) 2012-05-15 2013-11-21 Morphotek, Inc. Methods for treatment of gastric cancer
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
JP2015520179A (ja) 2012-06-06 2015-07-16 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ワクチン
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
CN104583230A (zh) 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
CA2880007C (en) 2012-07-25 2021-12-28 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
NO2760138T3 (fi) 2012-10-01 2018-08-04
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP3721942A1 (en) 2012-10-15 2020-10-14 Medimmune Limited Antibodies to amyloid beta
BR112015009306A2 (pt) 2012-10-24 2017-08-22 Nat Res Council Canada Anticorpos anti-campylobacter jejuni e usos dos mesmos
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
KR102408660B1 (ko) 2012-11-20 2022-06-15 사노피 항-ceacam5 항체 및 이의 용도
EP2925779A1 (en) 2012-11-30 2015-10-07 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP2016505843A (ja) 2012-12-19 2016-02-25 アンプリミューン， インコーポレイテッド Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9790277B2 (en) 2012-12-21 2017-10-17 The Johns Hopkins University Anti-H7CR antibodies
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
EP3400961B1 (en) 2012-12-27 2021-02-24 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
ES2865735T3 (es) 2013-01-28 2021-10-15 Evec Inc Anticuerpo anti-hmgb1 humanizado o fragmento de unión a antígeno del mismo
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
US9394368B2 (en) 2013-02-20 2016-07-19 Novartis Ag Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US20160022813A1 (en) 2013-03-13 2016-01-28 Sanofi Compositions comprising anti-cd38 antibodies and carfilzomib
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
EP3564384A1 (en) 2013-03-14 2019-11-06 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
BR112015023086A2 (pt) 2013-03-15 2017-11-21 Abbvie Biotechnology Ltd anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014145000A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
BR112015022119A2 (pt) 2013-03-15 2017-08-29 Abbvie Biotherapeutics Inc Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
PL2981822T4 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
JP6682426B2 (ja) 2013-05-24 2020-04-15 メディミューン，エルエルシー 抗ｂ７−ｈ５抗体およびその使用
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP4067383A1 (en) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JPWO2015033831A1 (ja) 2013-09-04 2017-03-02 国立大学法人大阪大学 Ｄｐｐ−４を標的とした糖尿病治療用ワクチン
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
ES2773306T3 (es) 2013-09-16 2020-07-10 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Polipéptidos bi o multiespecíficos de unión a antígenos de superficie de células efectoras inmunitarias y antígenos de VHB para tratar infecciones por VHB y estados asociados
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
MX2016005170A (es) 2013-10-25 2017-02-02 Psioxus Therapeutics Ltd Adenovirus oncoliticos armados con genes heterologos.
JP2016536018A (ja) 2013-10-28 2016-11-24 ドッツ テクノロジー コーポレイションＤＯＴＳ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． アレルゲン検出
NZ719784A (en) 2013-10-31 2022-02-25 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
JP6449876B2 (ja) 2013-11-07 2019-01-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
AU2014365838B2 (en) 2013-12-16 2021-01-14 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
PT3083680T (pt) 2013-12-20 2020-03-17 Hoffmann La Roche Anticorpos humanizados anti-tau(ps422) e métodos de utilização
JP6164593B2 (ja) 2013-12-27 2017-07-19 国立大学法人大阪大学 Ｉｌ−１７ａを標的とするワクチン
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102355308B1 (ko) 2014-03-06 2022-01-24 내셔날 리서치 카운실 오브 캐나다 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
AU2014385801B2 (en) 2014-03-06 2020-11-12 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
DK3114141T3 (da) 2014-03-06 2020-08-10 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
CN106164094B (zh) 2014-03-21 2021-05-14 X博迪公司 双特异性抗原结合多肽
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
IL293603B2 (en) 2014-04-07 2024-03-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3131929B1 (en) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
HUE053287T2 (hu) 2014-04-30 2021-06-28 Pfizer PTK-7 elleni ellenanyag-drog konjugátumok
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
TW202132337A (zh) 2014-05-28 2021-09-01 美商艾吉納斯公司 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
EP3154579A1 (en) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research New treatment against influenza virus
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP3164129A1 (en) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
SG11201700250WA (en) 2014-07-17 2017-02-27 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP6721568B2 (ja) 2014-07-29 2020-07-15 セレクティスＣｅｌｌｅｃｔｉｓ がん免疫療法のためのｒｏｒ１（ｎｔｒｋｒ１）特異的キメラ抗原レセプター
EP3660042B1 (en) 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
CA2956482A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
PT3183268T (pt) 2014-08-19 2020-05-15 Novartis Ag Recetor de antigénio quimérico (car) anti-cd123 para uso no tratamento de cancro
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
DK3189073T3 (da) 2014-09-04 2020-03-30 Cellectis Trophoblast-glycoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi
RS60305B1 (sr) 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
EP3204411A4 (en) 2014-10-10 2018-03-28 National Research Council of Canada Anti-tau antibody and uses thereof
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3218394A1 (en) 2014-11-12 2017-09-20 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3546567A1 (en) 2014-12-06 2019-10-02 GEMoaB Monoclonals GmbH Genetic modified pluri- or multipotent stem cells and uses thereof
BR112017012351A2 (pt) 2014-12-09 2018-02-27 Abbvie Inc compostos inibidores de bcl xl que têm permeabilidade celular baixa e conjugados de fármaco-anticorpo que incluem os mesmos
BR112017012377A2 (pt) 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CA2971517A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
CN107406509B (zh) * 2014-12-19 2021-10-29 凯奥目生物科学株式会社 包含结合至5t4和cd3的三个结合结构域的融合蛋白
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
JP7152156B2 (ja) 2015-01-14 2022-10-12 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 抗ｌａｐモノクローナル抗体による癌の処置
LT3247725T (lt) 2015-01-23 2020-10-12 Sanofi Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
CN107438618A (zh) 2015-01-26 2017-12-05 塞勒克提斯公司 赋予结合至cd123的嵌合抗原受体用于治疗复发性/难治性急性骨髓性淋巴瘤或母细胞性浆细胞样树突状细胞肿瘤的t细胞受体敲除的工程化免疫细胞
JP7170394B2 (ja) 2015-01-31 2022-11-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 治療用分子のｔ細胞送達のための組成物および方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US10266584B2 (en) 2015-02-09 2019-04-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
SI3265123T1 (sl) 2015-03-03 2023-02-28 Kymab Limited Protitelesa, uporabe in postopki
EP3265483B1 (en) 2015-03-06 2019-12-11 CSL Behring Lengnau AG Modified von willebrand factor having improved half-life
CN116064731A (zh) 2015-03-13 2023-05-05 哈佛学院院长及董事 使用扩增测定细胞
AU2016233309B2 (en) 2015-03-17 2021-11-18 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016162368A1 (en) 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-invasive imaging of tumor pd-l1 expression
KR20170134642A (ko) 2015-04-08 2017-12-06 노파르티스 아게 Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3290441B1 (en) 2015-04-28 2019-10-30 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
MX2017013807A (es) 2015-04-30 2018-03-15 Harvard College Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos.
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
MA42059A (fr) 2015-05-06 2018-03-14 Janssen Biotech Inc Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
MX2017014188A (es) 2015-05-07 2018-04-10 Agenus Inc Anticuerpos anti-ox40 y metodos para su uso.
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
FI3447075T3 (fi) 2015-05-15 2023-11-07 Massachusetts Gen Hospital Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
LT3303394T (lt) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
KR102661078B1 (ko) 2015-05-29 2024-05-23 애브비 인코포레이티드 항-ｃｄ40 항체 및 그의 용도
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
EP3319983A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
EP3319984A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
EP3319990A1 (en) 2015-07-07 2018-05-16 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies having specificity to myosin 18a and uses thereof
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
RU2018107754A (ru) 2015-08-11 2019-09-12 Селлектис Клетки для иммунотерапии, созданные для таргетинга антигена cd38 и для инактивации гена cd38
WO2017040195A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11890301B2 (en) 2015-08-28 2024-02-06 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
AU2016326449A1 (en) 2015-09-21 2018-03-22 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6931648B2 (ja) 2015-10-27 2021-09-08 ユーシービー バイオファルマ エスアールエル 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
EP3368567A4 (en) 2015-10-28 2019-05-22 Yale University HUMANIZED ANTI-DKK2 ANTIBODIES AND USES THEREOF
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
CA3003759A1 (en) 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
DK3380525T3 (da) 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
EP3383909B1 (en) 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
CA3006769A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
WO2017096361A1 (en) 2015-12-04 2017-06-08 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN116063492A (zh) 2015-12-15 2023-05-05 昂科医药 嵌合和人源化抗人类ctla4单克隆抗体和其用途
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
JP6940505B2 (ja) 2015-12-31 2021-09-29 シンセラス、エス、アー エル、エルＳｙｎｃｅｒｕｓ Ｓ．Ａ Ｒ．Ｌ． 組成物および癌の発生リスクの評価方法
ES2847155T3 (es) 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
BR112018067525A2 (pt) 2016-02-26 2019-02-05 Centre Nat Rech Scient anticorpos tendo especificidade para o btla e seus usos
AR107786A1 (es) 2016-03-02 2018-06-06 Idexx Lab Inc Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
CN109153714A (zh) 2016-03-04 2019-01-04 诺华股份有限公司 表达多重嵌合抗原受体(car)分子的细胞及其用途
TW201742625A (zh) 2016-03-15 2017-12-16 阿斯特捷利康公司 組合療法
KR102449711B1 (ko) 2016-03-17 2022-09-30 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
RS61412B1 (sr) 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
MA43715A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels correspondants
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
AU2017235465B2 (en) 2016-03-17 2024-03-28 Numab Therapeutics AG Anti-TNFα-antibodies and functional fragments thereof
KR20220004226A (ko) 2016-03-22 2022-01-11 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
AU2017244108B2 (en) 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
IL312206A (en) 2016-04-15 2024-06-01 Novartis Ag Preparations and methods for selective protein expression
EP4276108A3 (en) 2016-04-27 2024-01-24 AbbVie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
BR112018071288A2 (pt) 2016-05-01 2019-02-26 Ucb Biopharma Sprl dominio de ligação de carreador de proteína sérica de afinidade modificada
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
SI3626273T1 (sl) 2016-05-17 2021-04-30 Abbvie Biotherapeutics Inc. Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
EP3464360A1 (en) 2016-05-27 2019-04-10 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
CA3025347A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-cd40 antibodies and their uses
WO2017205745A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US10640563B2 (en) 2016-06-08 2020-05-05 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MY190771A (en) 2016-06-13 2022-05-12 I Mab Biopharma Us Ltd Anti-pd-l1 antibodies and uses thereof
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JP2019532017A (ja) 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014122A1 (en) 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN118021943A (zh) 2016-07-28 2024-05-14 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
EP3491022A1 (en) 2016-07-29 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies targeting tumor associated macrophages and uses thereof
CA3032581A1 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CN109923129A (zh) 2016-08-26 2019-06-21 新加坡科技研究局 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途
CN109862912A (zh) 2016-08-29 2019-06-07 皮斯奥克斯治疗公司 携带双特异性T细胞衔接器（BiTE）的腺病毒
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
IL265179B2 (en) 2016-09-14 2024-02-01 Abbvie Biotherapeutics Inc Antibodies against PD-1 (CD27)
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR102356187B1 (ko) 2016-09-19 2022-02-08 아이-맵 바이오파마 (항저우) 컴퍼니 리미티드 항-gm-csf 항체 및 이것의 사용
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS CIBLANG PSMA AND METHODS OF USE
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
MX2019007121A (es) 2016-12-15 2020-02-05 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos.
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
JP7254699B2 (ja) 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
UY37544A (es) 2016-12-22 2018-07-31 Sanofi Sa Anticuerpos humanizados contra cxcr3 con actividad mermadora y métodos de uso de los mismos
KR102679324B1 (ko) 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
JP7069476B2 (ja) 2017-01-06 2022-05-18 博奥信生物技▲術▼（南京）有限公司 ＥｒｂＢ２抗体およびその使用
KR102536145B1 (ko) 2017-01-20 2023-05-30 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 항-pd-1 항체 및 이의 용도
KR102156199B1 (ko) 2017-01-24 2020-09-17 아이-맵 바이오파마 유에스 리미티드 항-cd73 항체 및 이것의 사용
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
JP7237848B2 (ja) 2017-03-27 2023-03-13 セルジーン コーポレイション 免疫原性の低下のための方法及び組成物
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
MX2019012223A (es) 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
JP7289420B6 (ja) 2017-04-14 2023-06-30 エクセリクシス， インク． 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物
WO2018189379A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
KR20190141659A (ko) 2017-04-21 2019-12-24 스태튼 바이오테크놀로지 비.브이. 항-apoc3 항체 및 이의 사용 방법
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CA3062061A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
KR20220147684A (ko) * 2017-05-10 2022-11-03 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 최적화된 핵산 항체 작제물
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
AU2018266562A1 (en) 2017-05-12 2019-12-05 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific T cell receptors and uses thereof
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
MX2019014184A (es) 2017-06-01 2020-08-03 Psioxus Therapeutics Ltd Virus oncoliticos y metodo.
SG10202113337YA (en) 2017-06-02 2021-12-30 Ablynx Nv Aggrecan binding immunoglobulins
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
BR112019026803A2 (pt) 2017-06-20 2020-06-30 Teneoone, Inc. anticorpos apenas de cadeia pesada anti-bcma
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
US20190048073A1 (en) 2017-07-20 2019-02-14 Pfizer Inc. Anti-gd3 antibodies and antibody-drug conjugates
EP3658581A1 (en) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
AU2018306436A1 (en) 2017-07-27 2020-02-13 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
WO2019046338A1 (en) 2017-08-28 2019-03-07 Angiex, Inc. ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
CA3074933A1 (en) 2017-09-21 2019-03-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
CN112020648A (zh) 2017-10-04 2020-12-01 赫斯佩瑞克斯股份公司 针对癌症个体化疗法的制品和方法
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US11332527B2 (en) 2017-10-12 2022-05-17 Keio University Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
EP3694529B1 (en) 2017-10-13 2024-06-26 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
SG11202003341UA (en) 2017-10-13 2020-05-28 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
US11730763B2 (en) 2017-11-14 2023-08-22 Arcellx, Inc. Multifunctional immune cell therapies
CA3083345A1 (en) 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
US20210085715A1 (en) 2018-02-23 2021-03-25 Cartherics Pty. Ltd. T cell disease treatment targeting tag-72
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
MA52190A (fr) 2018-04-02 2021-02-17 Bristol Myers Squibb Co Anticorps anti-trem-1 et utilisations associées
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
KR20210015902A (ko) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
CN112867394A (zh) 2018-06-04 2021-05-28 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
SG11202012312UA (en) 2018-06-18 2021-01-28 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
AU2019288677A1 (en) 2018-06-21 2021-01-14 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
EP3814369A1 (en) 2018-06-29 2021-05-05 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
TW202019481A (zh) 2018-07-10 2020-06-01 日商田邊三菱製藥股份有限公司 末稍神經障礙或伴隨著觀察到末稍神經障礙或星狀細胞障礙之疾病的疼痛之預防或治療方法
AU2019306165A1 (en) 2018-07-20 2021-02-25 Pierre Fabre Medicament Receptor for vista
CN112739340A (zh) 2018-07-23 2021-04-30 美真达治疗公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
AR116048A1 (es) 2018-08-30 2021-03-25 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
KR20210089143A (ko) 2018-09-18 2021-07-15 메리맥 파마슈티컬즈, 인크. 항-tnfr2 항체 및 그의 용도
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
CA3114295A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US20220026445A1 (en) 2018-12-07 2022-01-27 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
CA3123004A1 (en) 2018-12-11 2020-06-18 Q32 Bio Inc. Fusion protein constructs for complement associated disease
JP2022516408A (ja) 2018-12-14 2022-02-28 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
CA3124356A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
CA3127776A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
AU2020215795A1 (en) 2019-01-31 2021-07-29 Numab Therapeutics AG Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
WO2020162452A1 (ja) 2019-02-04 2020-08-13 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
EP3929212A4 (en) 2019-02-22 2022-11-23 Wuhan Yzy Biopharma Co., Ltd. MODIFIED FC FRAGMENT, ANTIBODY COMPRISING THEM AND THEIR APPLICATION
CA3131036A1 (en) 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
JP2022522344A (ja) 2019-02-26 2022-04-18 インスピアーナ， インコーポレイテッド 高親和性抗ｍｅｒｔｋ抗体およびその使用
WO2020180712A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
SG11202109932WA (en) 2019-03-20 2021-10-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
JP2022528324A (ja) 2019-03-26 2022-06-10 アスラン ファーマシューティカルズ ピーティーイー リミテッド 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療
CN113874392A (zh) 2019-03-28 2021-12-31 丹尼斯科美国公司 工程化抗体
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
US20210139585A1 (en) 2019-05-21 2021-05-13 Novartis Ag Cd19 binding molecules and uses thereof
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
CN113968910A (zh) 2019-07-11 2022-01-25 武汉友芝友生物制药有限公司 四价对称双特异性抗体
JP2022542431A (ja) 2019-07-30 2022-10-03 キューエルエスエフ バイオセラピューティクス， インコーポレイテッド 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体
JP2022543259A (ja) 2019-08-02 2022-10-11 オレガ・バイオテック 新規ｉｌ－１７ｂ抗体
CA3150762A1 (en) 2019-08-12 2021-02-18 Aptevo Research And Development Llc 4-1 bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1 bb, antibodies against ox40
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
WO2021043206A1 (zh) 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
JP2022550325A (ja) 2019-09-27 2022-12-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗ミュラー管抑制物質抗体およびその使用
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
WO2021099600A1 (en) 2019-11-22 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
WO2021116277A1 (en) 2019-12-10 2021-06-17 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
US20230055626A1 (en) 2020-01-15 2023-02-23 Osaka University Agent for prevention or treatment of diabetic autonomic neuropathy
AU2021207010A1 (en) 2020-01-15 2022-08-25 Mitsubishi Tanabe Pharma Corporation Prophylactic or therapeutic agent for dementia
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4100435A1 (en) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
US20230151109A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9
US20230192900A1 (en) 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
US20230096030A1 (en) 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
EP4110404A1 (en) 2020-02-28 2023-01-04 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
JP2023516080A (ja) 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
KR20220167276A (ko) 2020-03-10 2022-12-20 매사추세츠 인스티튜트 오브 테크놀로지 NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
WO2021197340A1 (zh) 2020-03-31 2021-10-07 百奥泰生物制药股份有限公司 用于治疗冠状病毒的抗体、融合蛋白及其应用
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
IL297221A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and folfiri
JP2023522395A (ja) 2020-04-24 2023-05-30 サノフイ 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフォックスを含有する抗腫瘍組み合わせ
CA3180872A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
IL297207A (en) 2020-04-24 2022-12-01 Sanofi Sa Combinations against tumors containing conjugates of antibodies to trifluridine, ceacam5 and tipiracil
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
CN116157510A (zh) 2020-06-17 2023-05-23 詹森生物科技公司 用于制造多能干细胞的材料和方法
CN116209478A (zh) 2020-07-17 2023-06-02 田边三菱制药株式会社 肌病的预防或治疗剂
WO2022028608A1 (zh) 2020-08-07 2022-02-10 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
CA3190586A1 (en) 2020-09-04 2022-03-10 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
KR20230104157A (ko) 2020-10-07 2023-07-07 조에티스 서비시즈 엘엘씨 항-ngf 항체 및 그의 사용 방법
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
CA3198049A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
US20240084014A1 (en) 2020-10-16 2024-03-14 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP4237081A1 (en) 2020-11-02 2023-09-06 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
JP2023551113A (ja) 2020-11-06 2023-12-07 バイオ－テラ ソリュ－ションズ，エルティーディー． 二重特異性抗体及びその応用
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
WO2022104061A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
JP2023551981A (ja) 2020-12-07 2023-12-13 ユーシービー バイオファルマ エスアールエル 多重特異性抗体及び抗体の組み合わせ
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240092892A1 (en) 2020-12-30 2024-03-21 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and preparation method therefor and use thereof
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
EP4281187A1 (en) 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
JP2024508157A (ja) 2021-03-04 2024-02-22 センター ナショナル デ ラ レシェルシェ サイエンティフィーク 炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
BR112023017490A2 (pt) 2021-03-17 2023-11-07 Receptos Llc Métodos de tratamento de dermatite atópica com anticorpos anti il-13
IL307168A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Humanized antibodies against paired helical strands of TAU protein and their uses
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3218933A1 (en) 2021-05-03 2022-11-10 UCB Biopharma SRL Antibodies
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
EP4334354A1 (en) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
IL310437A (en) 2021-07-29 2024-03-01 Inst Nat Sante Rech Med Humanized anti-human βig-h3 protein and uses thereof
AU2022318416A1 (en) 2021-07-29 2024-01-25 Takeda Pharmaceutical Company Limited Engineered immune cell that specifically targets mesothelin and uses thereof
EP4380604A1 (en) 2021-08-05 2024-06-12 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CN118019548A (zh) 2021-08-06 2024-05-10 蒙彼利埃癌症研究所 用于治疗癌症的方法
WO2023019200A1 (en) 2021-08-11 2023-02-16 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
EP4395810A1 (en) 2021-09-03 2024-07-10 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
KR20240101546A (ko) 2021-09-03 2024-07-02 고 테라퓨틱스, 인크. 항-글리코-lamp1 항체 및 그의 용도
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
CN115894689A (zh) 2021-09-30 2023-04-04 百奥泰生物制药股份有限公司 抗b7-h3抗体及其应用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
AU2022396272A1 (en) 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
CA3241407A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023116911A1 (zh) 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
AR128222A1 (es) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
WO2023163659A1 (en) 2022-02-23 2023-08-31 Aslan Pharmaceuticals Pte Ltd Glycosylated form of anti-il13r antibody
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
WO2023170239A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Methods and tools for conjugation to antibodies
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
TW202400636A (zh) 2022-03-11 2024-01-01 比利時商健生藥品公司 多特異性抗體及其用途(一)
TW202345899A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
GB202210680D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-35r
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024115393A1 (en) 2022-11-28 2024-06-06 UCB Biopharma SRL Treatment of fibromyalgia
GB202217923D0 (en) 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133052A1 (en) 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
WO2024138144A1 (en) * 2022-12-22 2024-06-27 The Medical College Of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5062934A (en) * 1989-12-18 1991-11-05 Oronzio Denora S.A. Method and apparatus for cathodic protection
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
ES2289997T3 (es) * 1991-03-18 2008-02-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
JPH06202412A (ja) * 1992-12-26 1994-07-22 Canon Inc 画像形成装置
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5535089A (en) * 1994-10-17 1996-07-09 Jing Mei Industrial Holdings, Ltd. Ionizer

Also Published As

Publication number Publication date
US20050202529A1 (en) 2005-09-15
CA2037607C (en) 2005-05-24
DK0460178T3 (da) 1997-12-22
KR100191152B1 (ko) 1999-06-15
GR3017734T3 (en) 1996-01-31
FI108776B (fi) 2002-03-28
JPH11243955A (ja) 1999-09-14
NO985467D0 (no) 1998-11-23
EP0626390A1 (en) 1994-11-30
NO310560B1 (no) 2001-07-23
NO913229D0 (no) 1991-08-19
HU215383B (hu) 2000-03-28
GB9117612D0 (en) 1991-11-20
CA2046904A1 (en) 1991-06-22
US20050136054A1 (en) 2005-06-23
AU6974091A (en) 1991-07-24
JP3452062B2 (ja) 2003-09-29
GB2268744B (en) 1994-05-11
BG95018A (bg) 1993-12-24
NO913271L (no) 1991-08-20
HU912751D0 (en) 1992-01-28
BR9007197A (pt) 1992-01-28
DE69020544T2 (de) 1996-01-18
EP0620276A1 (en) 1994-10-19
NO985468D0 (no) 1998-11-23
FI913932A0 (fi) 1991-08-20
ES2112270T3 (es) 1998-04-01
FI108917B (fi) 2002-04-30
GB2246570A (en) 1992-02-05
CA2037607A1 (en) 1992-09-07
EP0460178B1 (en) 1997-10-15
DE69020544D1 (de) 1995-08-03
FI913927A0 (fi) 1991-08-20
GB9318911D0 (en) 1993-10-27
NO913228D0 (no) 1991-08-19
US5929212A (en) 1999-07-27
FI990875A (fi) 1999-04-19
RO114298B1 (ro) 1999-03-30
JP3242913B2 (ja) 2001-12-25
CA2050479A1 (en) 1991-06-22
KR100198478B1 (en) 1999-06-15
EP0460171A1 (en) 1991-12-11
AU7033091A (en) 1991-07-24
EP0460178A1 (en) 1991-12-11
US7244832B2 (en) 2007-07-17
NO316074B1 (no) 2003-12-08
EP0626390B1 (en) 2001-11-14
HU912752D0 (en) 1992-01-28
WO1991009967A1 (en) 1991-07-11
NO985467L (no) 1991-10-21
RU2112037C1 (ru) 1998-05-27
FI913926A0 (fi) 1991-08-20
US20040071693A1 (en) 2004-04-15
FI108777B (fi) 2002-03-28
WO1991009966A1 (en) 1991-07-11
US20060073137A1 (en) 2006-04-06
DE69022982T2 (de) 1996-03-28
HUT58824A (en) 1992-03-30
KR920701465A (ko) 1992-08-11
ATE159299T1 (de) 1997-11-15
DE69031591T2 (de) 1998-03-12
US20040076627A1 (en) 2004-04-22
US20060029593A1 (en) 2006-02-09
EP0460167B1 (en) 1995-10-11
NO913229L (no) 1991-10-21
EP0460171B1 (en) 1995-06-28
US7262050B2 (en) 2007-08-28
DE69033857T2 (de) 2002-09-12
CA2050479C (en) 1997-03-25
DE69033857D1 (de) 2001-12-20
GB2268744A (en) 1994-01-19
AU6461294A (en) 1994-12-22
KR100197956B1 (ko) 1999-06-15
DK0460167T3 (da) 1995-11-20
DE69022982D1 (de) 1995-11-16
GB9117611D0 (en) 1991-10-02
AU649645B2 (en) 1994-06-02
US7244615B2 (en) 2007-07-17
GB8928874D0 (en) 1990-02-28
FI109768B (fi) 2002-10-15
ZA9110129B (en) 1993-06-23
US7241877B2 (en) 2007-07-10
NO913228L (no) 1991-10-21
RO114980B1 (ro) 1999-09-30
DK0460171T3 (da) 1995-08-28
HUT60786A (en) 1992-10-28
ES2079638T3 (es) 1996-01-16
JPH04506458A (ja) 1992-11-12
GB2246781B (en) 1994-05-11
BG60462B1 (bg) 1995-04-28
WO1991009968A1 (en) 1991-07-11
EP0460167A1 (en) 1991-12-11
RO114232B1 (ro) 1999-02-26
AU631481B2 (en) 1992-11-26
ES2165864T3 (es) 2002-04-01
GR3025781T3 (en) 1998-03-31
GB2246570B (en) 1994-05-11
US20040202662A1 (en) 2004-10-14
ATE124459T1 (de) 1995-07-15
HUT58372A (en) 1992-02-28
NO316076B1 (no) 2003-12-08
AU664801B2 (en) 1995-11-30
NO913271D0 (no) 1991-08-20
AU7048691A (en) 1991-07-24
DE69031591D1 (de) 1997-11-20
NO985468L (no) 1991-10-21
HU217693B (hu) 2000-03-28
ATE129017T1 (de) 1995-10-15
DK0626390T3 (da) 2002-03-11
AU646009B2 (en) 1994-02-03
ES2074701T3 (es) 1995-09-16
ATE208794T1 (de) 2001-11-15
GB2246781A (en) 1992-02-12
US20050123534A1 (en) 2005-06-09
JPH05500312A (ja) 1993-01-28
US20060073136A1 (en) 2006-04-06
JPH04505398A (ja) 1992-09-24
CA2046904C (en) 2003-12-02

Similar Documents

Publication Publication Date Title
FI990875A0 (fi) CD4-spesifinen yhdistelmävasta-aine
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
ES2116790T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.